US regulators sue ‘pharma bro’ Shkreli over drug monopoly

The US Federal Trade Commission (FTC) and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim (pyrimethamine).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

States join antitrust suit against ‘pharma bro’ Shkreli

16 April 2020 Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.

Americas

Shkreli says he isn’t responsible for Daraprim ‘monopoly’

30 July 2020 Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.

Big Pharma

UK regulators no longer exempt from paying successful parties' costs

26 May 2022 The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.

More on this story

Americas

States join antitrust suit against ‘pharma bro’ Shkreli

Americas

Shkreli says he isn’t responsible for Daraprim ‘monopoly’

30 July 2020 Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.

Big Pharma

UK regulators no longer exempt from paying successful parties' costs

More on this story

Americas

States join antitrust suit against ‘pharma bro’ Shkreli

Americas

Shkreli says he isn’t responsible for Daraprim ‘monopoly’

30 July 2020 Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.

Big Pharma

UK regulators no longer exempt from paying successful parties' costs